Tag: major depressive disorder

Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment

businessnewstoday- August 5, 2023

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults ... Read More

Granules India gets Venlafaxine ER Capsules FDA approval

businessnewstoday- May 19, 2023

Granules India has secured approval for its abbreviated new drug application (ANDA) for Venlafaxine Hydrochloride Extended-Release (ER) Capsules USP, 37.5 mg, 75 mg, and 150 ... Read More

Digital medicine firm Akili Interactive to merge with Social Capital Suvretta

businessnewstoday- January 29, 2022

Akili Interactive, a US-based digital medicine company, has agreed to merge with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC), ... Read More

Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen

pharmanewsdaily- November 29, 2020

Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for ... Read More

Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals

pharmanewsdaily- July 21, 2020

Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas ... Read More

Usona Institute gets FDA breakthrough status for psilocybin in MDD

pharmanewsdaily- November 23, 2019

Wisconsin-based Usona Institute has been granted breakthrough therapy designation for psilocybin from the US Food and Drug Administration (FDA) for the treatment of major depressive ... Read More